Compositions and systems for combination therapy comprising fucosylated stem cells and hematopoietic stimulants and / or immunotherapeutic agents, as well as methods for producing and using the same.

Combining ex vivo fucosylated stem cells with hematopoietic stimulants and immunotherapeutic agents addresses the dilution issue in HSCT, enhancing engraftment and recovery, thus improving the efficacy and safety of stem cell transplantation.

JP2026510338APending Publication Date: 2026-04-02TARGAZYME INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-03-08
Publication Date
2026-04-02

AI Technical Summary

Technical Problem

Hematopoietic stem cell transplantation (HSCT) is plagued by prolonged immunodeficiency and severe side effects due to the dilution of fucosylation on stem cell surfaces during cell division, leading to delayed engraftment and increased risks of infections and graft-versus-host disease.

Method used

Combining ex vivo fucosylated stem cells with hematopoietic stimulants and immunotherapeutic agents to enhance the migration and engraftment of stem cells, utilizing fucosylated mononuclear cells and hematopoietic stimulants like PEG-filgrastim to accelerate recovery and reduce side effects.

Benefits of technology

Significantly accelerates hematopoietic cell recovery, reduces infection risk, and enhances immune cell proliferation, thereby improving the success rate and safety of HSCT therapy for hematological malignancies and autoimmune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026510338000001_ABST
    Figure 2026510338000001_ABST
Patent Text Reader

Abstract

Disclosed are compositions, drugs, kits, and systems for hematopoietic stem cell transplantation therapy comprising surface-modified stem cells, hematopoietic stimulants, and / or monoclonal antibodies. The stem cells are ex vivo fucosylated and may be autologous or allogeneic. The hematopoietic stimulants may be leukocyte stimulants, erythrocyte stimulants, and / or platelet stimulants. Methods for manufacturing and / or using these compositions, drugs, kits, and systems are also disclosed. Methods for improving the engraftment rate of hematopoietic stem cells and myeloid cells in hematopoietic stem cell therapy are also disclosed.
Need to check novelty before this filing date? Find Prior Art